| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000019574 |
| Receipt No. | R000021795 |
| Official scientific title of the study | Effect of Denosumab and Alendronate on glucocorticoid-induced osteoporosis in patients with glomerulonephritis:a randomized controlled trial |
| Date of disclosure of the study information | 2015/10/30 |
| Last modified on | 2017/04/28 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Effect of Denosumab and Alendronate on glucocorticoid-induced osteoporosis in patients with glomerulonephritis:a randomized controlled trial
|
|
| Title of the study (Brief title) | Effect of Denosumab and Alendronate on glucocorticoid-induced osteoporosis in patients with glomerulonephritis:a randomized controlled trial | |
| Region |
|
|
| Condition | ||||
| Condition | Glucocorticoid-Induced Osteoporosis | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Others | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | The aim of this study is to evaluate the effect of denosumab and alendronate on glucocorticoidiunduced osteoporosis in patients with glomerulonephritis. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Percent change of bone mineral density (BMD) in lumber spine, femoral neck and distal radius at 6, 12 month after intervention |
| Key secondary outcomes | Percent change of bone metabolism markers, rate of continuation, side effect at 6, 12 month after intervention |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | denosumab (60 mg) subcutaneously every
6 months |
|
| Interventions/Control_2 | Alendronate (35 mg) by oral administration once a week | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) patients who meet the glucocorticoid- induced osteoporosis criteria
2) Patient whose age is more than 20 years old |
|||
| Key exclusion criteria | 1) Patients who are considered to be contraindicated for denosumab.
2) Patients who are considered to be contraindicated for alendronate. 3) Cancer patients. 4) Patients who have pretreated with bisphosphonate in recent 6 months. 5) Patients who have pretreated with denosumab in recent 6 months. 6) Patients whose eGFR is less than 35ml/min/1.73m2. 7) Patients whose i-PTH is more than 300ml/min. 8) Patients whose corrected Ca is less than 8.4 mg/dL. 9) Patients who are thought to be inappropriate for this study by physician. |
|||
| Target sample size | 30 | |||
| Research contact person | |
| Name of lead principal investigator | Masayuki Iyoda |
| Organization | Showa University School of Medicine
|
| Division name | Division of Nephrology, Department of Medicine |
| Address | 1-5-8 Hatanodai, Shinagawa-ku, Tokyo |
| TEL | 03-3784-8533 |
| iyoda@med.showa-u.ac.jp | |
| Public contact | |
| Name of contact person | Ken Iseri |
| Organization | Showa University School of Medicine |
| Division name | Division of Nephrology, Department of Medicine |
| Address | 1-5-8 Hatanodai, Shinagawa-ku, Tokyo |
| TEL | 03-3784-8533 |
| Homepage URL | |
| iseriken@med.showa-u.ac.jp | |
| Sponsor | |
| Institute | Showa University School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | none |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021795 |